The medical insurance bureau's "blacklist" first issued heavy penalties for commercial bribery: the main products of well-known pharmaceutical companies have been suspended from the Internet!

Medical Network, April 14 hearing on April 12, Zhejiang Pharmaceutical Equipment Procurement Center issued a notice stating that according to the criminal judgment of the People’s Court of Ouhai District, Wenzhou City, Zhejiang Province ("(2020) Zhejiang 0304 Xing Chu No.
428") In fact, the Lugua Polypeptide Injection of Harbin Yuheng Pharmaceutical Co.
, Ltd.
is involved in commercial bribery in Zhejiang Province.
In accordance with the “Guiding Opinions of the National Medical Security Administration on Establishing the Credit Evaluation System for Medicine Price and Recruitment and Purchasing”, “Zhejiang Pharmaceutical Price and Credit Evaluation System for Recruitment and Purchasing (Trial)” and other documents, Harbin Yuheng Pharmaceutical Co.
, Ltd.
was established in Zhejiang Province.
The price and the rating of untrustworthy recruitment were rated as "serious", and the company's online trading of Lugua Polypeptide Injection was suspended according to regulations.
Yuheng Pharmaceutical has become the first pharmaceutical company to be listed as a severe punishment for dishonesty since the National Medical Insurance Bureau established the medical price and recruitment credit evaluation system.

 

Commercial bribery of more than 800,000 yuan

 

Pharmaceutical companies are listed as seriously untrustworthy

 

The judgment notified by Zhejiang shows that since 2017, the defendant Ni Dongmin has contracted drug promotion business in Zhejiang from pharmaceutical companies such as Harbin Yuheng Pharmaceutical Co.
, Ltd.
, and then used Hangzhou Feite Company, Tianduan and Juhui respectively, and 39 companies.
In the name of an independent enterprise in Dongtou, a drug promotion contract was signed with a pharmaceutical factory.
After the defendant Ni Dongmin took the contract, he subcontracted the business to numerous medical representatives or the next subcontractor, including the defendant Lu Gang, and earned 5%-10% of the promotion fee.
5% of the invoice amount is deducted from the tax.
In the end, each medical representative is responsible for the promotion of drug business to hospitals and other drug users.

 

　　From May 2017 to June 26, 2019, after defendant Lu Gang obtained the promotion fee for Lugua polypeptide injection from Harbin Yuheng Pharmaceutical Co.
, Ltd.
from defendant Ni Dongmin, in order to increase sales, he promised to issue one deer per The standard of "Guarana Polypeptide" injection payment of 8 yuan benefit fee was given to the doctor at the First Affiliated Hospital of Wenzhou Medical University who prescribed the prescription, and the relevant doctor agreed.
During the period, the defendant Lu Gang paid a total of more than 880,000 yuan in benefits to 40 doctors such as Liu 3 and Chen 7 (in another case), of which the above-mentioned doctors directly or indirectly received more than 800,000 yuan in cash from other doctors.

 

　　Lugua polypeptide injection is the core product of Yuheng Pharmaceutical, but it has been adjusted in the 2019 edition of the National Medical Insurance Catalogue.

 

　　According to the relevant person in charge of the Price Recruitment Department of the National Medical Security Administration, the Party Central Committee and the State Council attach great importance to the prevention of high prices of drugs and medical consumables, and require strengthening of policy and management coordination to ensure that the masses receive high-quality and affordable medical services, and reduce the burden of medical treatment.
Improve people's livelihood and welfare However, outstanding problems such as rebates and monopoly price increases in the pharmaceutical field have long existed.
They are an important reason for high prices.
They have led to excessive growth of medical expenses, massive loss of medical insurance funds, overwhelming burdens, inducing excessive medical treatment, harming people’s health rights, and distortions.
The business environment and industry ecology weaken the industry's innovation motivation.

 

　　Taking the issue of drug rebates as an example, according to the statistics of publicly available court judgments, more than half of the 100 compulsory drug companies across the country from 2016 to 2019 were found to have given or indirectly given rebates, of which the most frequent companies were involved in the case for three years There were more than 20 cases, and the rebate amount in a single case exceeded 20 million yuan.
The average sales expense ratio of listed pharmaceutical companies exceeds 30%.

 

　　In this regard, the National Medical Insurance Administration proposed to establish a medical price and recruitment credit evaluation system, aiming to give play to the guiding and regulating role of the centralized pharmaceutical product procurement market, and to take appropriate measures against untrustworthy pharmaceutical companies that have outstanding problems such as rebates and monopoly price increases to promote Pharmaceutical companies set prices in accordance with the principles of "fairness, reasonableness, honesty and credibility, and conformity with quality and price" to promote the return of reasonable prices of pharmaceutical products and safeguard the vital interests of the people.

 

　　Untrustworthy behavior involves a certain number of provinces

 

　　National joint disposal will be initiated

 

　　In accordance with the requirements of the National Medical Insurance Bureau, provincial centralized procurement agencies implement credit ratings in accordance with the requirements of reliable sources, clear conditions, standardized procedures, and rigorous operations.
According to the nature, circumstances, timeliness, and impact of untrustworthy behaviors, pharmaceutical companies are invited to pharmnet.
com.
cn/news/yyzb/" target="_blank">bid for procurement locally.
The market’s untrustworthiness is assessed into four levels: general, moderate, serious, and particularly serious, and is updated quarterly.
For untrustworthy conduct involving violations of laws and regulations, and the facts on which credit ratings are based, the facts determined by court judgments or administrative penalty decisions shall prevail.

 

　　Provincial centralized procurement agencies, based on the credit ratings of pharmaceutical companies, adopt written reminders and warnings, rely on the centralized procurement platform to prompt purchasers of risk information, restrict or suspend the listing of relevant drugs or medical consumables, restrict or suspend the procurement of relevant drugs or medical consumables, and disclose Disposal measures such as untrustworthy information, where the number of provinces involved in untrustworthy conduct meets the prescribed conditions, the National Medical Insurance Administration's Medical Price and Bidding Procurement Guidance Center will initiate a national joint disposal.

 

　　The relevant person in charge of the aforementioned medical insurance bureau pointed out that the national medical insurance bureau will give full play to various functions such as medical price, bidding and procurement, and take the initiative to actively promote the effective management of medical rebates.
Pharmaceutical companies are often insensitive to the fines of rebate cases, but giving rebates will result in the loss of access to the centralized procurement market, which will produce a powerful deterrent effect, thereby forming a systematic governance effect by analogy.

 

　　The industry believes that under the combination of policies such as the medical price, recruitment and procurement credit evaluation system, and the medical representative filing system, the medical marketing model will become more standardized, and the academic promotion of the clinical value of the product will be the way out, and the medical representative team will also accelerate the professionalization Transformation.

　　Medical Network, April 14 hearing on April 12, Zhejiang Pharmaceutical Equipment Procurement Center issued a notice stating that according to the criminal judgment of the People’s Court of Ouhai District, Wenzhou City, Zhejiang Province ("(2020) Zhejiang 0304 Xing Chu No.
428") In fact, the Lugua Polypeptide Injection of Harbin Yuheng Pharmaceutical Co.
, Ltd.
is involved in commercial bribery in Zhejiang Province.
In accordance with the “Guiding Opinions of the National Medical Security Administration on Establishing the Credit Evaluation System for Medicine Price and Recruitment and Purchasing”, “Zhejiang Pharmaceutical Price and Credit Evaluation System for Recruitment and Purchasing (Trial)” and other documents, Harbin Yuheng Pharmaceutical Co.
, Ltd.
was established in Zhejiang Province.
The price and the rating of untrustworthy recruitment were rated as "serious", and the company's online trading of Lugua Polypeptide Injection was suspended according to regulations.
Yuheng Pharmaceutical has become the first pharmaceutical company to be listed as a severe punishment for dishonesty since the National Medical Insurance Bureau established the medical price and recruitment credit evaluation system.

 

　　Commercial bribery of more than 800,000 yuan

 

　　Pharmaceutical companies are listed as seriously untrustworthy

 

　　The judgment notified by Zhejiang shows that since 2017, the defendant Ni Dongmin has contracted drug promotion business in Zhejiang from pharmaceutical companies such as Harbin Yuheng Pharmaceutical Co.
, Ltd.
, and then used Hangzhou Feite Company, Tianduan and Juhui respectively, and 39 companies.
In the name of an independent enterprise in Dongtou, a drug promotion contract was signed with a pharmaceutical factory.
After the defendant Ni Dongmin took the contract, he subcontracted the business to numerous medical representatives or the next subcontractor, including the defendant Lu Gang, and earned 5%-10% of the promotion fee.
5% of the invoice amount is deducted from the tax.
In the end, each medical representative is responsible for the promotion of drug business to hospitals and other drug users.

 

　　From May 2017 to June 26, 2019, after defendant Lu Gang obtained the promotion fee for Lugua polypeptide injection from Harbin Yuheng Pharmaceutical Co.
, Ltd.
from defendant Ni Dongmin, in order to increase sales, he promised to issue one deer per The standard of "Guarana Polypeptide" injection payment of 8 yuan benefit fee was given to the doctor at the First Affiliated Hospital of Wenzhou Medical University who prescribed the prescription, and the relevant doctor agreed.
During the period, the defendant Lu Gang paid a total of more than 880,000 yuan in benefits to 40 doctors such as Liu 3 and Chen 7 (in another case), of which the above-mentioned doctors directly or indirectly received more than 800,000 yuan in cash from other doctors.

 

　　Lugua polypeptide injection is the core product of Yuheng Pharmaceutical, but it has been adjusted in the 2019 edition of the National Medical Insurance Catalogue.

 

　　According to the relevant person in charge of the Price Recruitment Department of the National Medical Security Administration, the Party Central Committee and the State Council attach great importance to the prevention of high prices of drugs and medical consumables, and require strengthening of policy and management coordination to ensure that the masses receive high-quality and affordable medical services, and reduce the burden of medical treatment.
Improve people's livelihood and welfare However, outstanding problems such as rebates and monopoly price increases in the pharmaceutical field have long existed.
They are an important reason for high prices.
They have led to excessive growth of medical expenses, massive loss of medical insurance funds, overwhelming burdens, inducing excessive medical treatment, harming people’s health rights, and distortions.
The business environment and industry ecology weaken the industry's innovation motivation.

 

　　Taking the issue of drug rebates as an example, according to the statistics of publicly available court judgments, more than half of the 100 compulsory drug companies across the country from 2016 to 2019 were found to have given or indirectly given rebates, of which the most frequent companies were involved in the case for three years There were more than 20 cases, and the rebate amount in a single case exceeded 20 million yuan.
The average sales expense ratio of listed pharmaceutical companies exceeds 30%.

 

　　In this regard, the National Medical Insurance Administration proposed to establish a medical price and recruitment credit evaluation system, aiming to give play to the guiding and regulating role of the centralized pharmaceutical product procurement market, and to take appropriate measures against untrustworthy pharmaceutical companies that have outstanding problems such as rebates and monopoly price increases to promote Pharmaceutical companies set prices in accordance with the principles of "fairness, reasonableness, honesty and credibility, and conformity with quality and price" to promote the return of reasonable prices of pharmaceutical products and safeguard the vital interests of the people.

 

　　Untrustworthy behavior involves a certain number of provinces

 

　　National joint disposal will be initiated

 

　　In accordance with the requirements of the National Medical Insurance Bureau, provincial centralized procurement agencies implement credit ratings in accordance with the requirements of reliable sources, clear conditions, standardized procedures, and rigorous operations.
According to the nature, circumstances, timeliness, and impact of untrustworthy behaviors, pharmaceutical companies are invited to pharmnet.
com.
cn/news/yyzb/" target="_blank">bid for procurement locally.
The market’s untrustworthiness is assessed into four levels: general, moderate, serious, and particularly serious, and is updated quarterly.
For untrustworthy conduct involving violations of laws and regulations, and the facts on which credit ratings are based, the facts determined by court judgments or administrative penalty decisions shall prevail.

 

　　Provincial centralized procurement agencies, based on the credit ratings of pharmaceutical companies, adopt written reminders and warnings, rely on the centralized procurement platform to prompt purchasers of risk information, restrict or suspend the listing of relevant drugs or medical consumables, restrict or suspend the procurement of relevant drugs or medical consumables, and disclose Disposal measures such as untrustworthy information, where the number of provinces involved in untrustworthy conduct meets the prescribed conditions, the National Medical Insurance Administration's Medical Price and Bidding Procurement Guidance Center will initiate a national joint disposal.

 

　　The relevant person in charge of the aforementioned medical insurance bureau pointed out that the national medical insurance bureau will give full play to various functions such as medical price, bidding and procurement, and take the initiative to actively promote the effective management of medical rebates.
Pharmaceutical companies are often insensitive to the fines of rebate cases, but giving rebates will result in the loss of access to the centralized procurement market, which will produce a powerful deterrent effect, thereby forming a systematic governance effect by analogy.

 

　　The industry believes that under the combination of policies such as the medical price, recruitment and procurement credit evaluation system, and the medical representative filing system, the medical marketing model will become more standardized, and the academic promotion of the clinical value of the product will be the way out, and the medical representative team will also accelerate the professionalization Transformation.